2Zanoffi K M,Belinson J L,Kennedy A W,et al.The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma[J].Gynecol Oncol,1999,74:272. 被引量：1
3Sikora K.Treatment of Cancer[M].London:Chapman and Hall Medical,1990.139. 被引量：1
4Wienik P H,Schwartz E L,Einzig A,et al.I trial of taxol given as a 24hour infusion every 21 days:responses observed in metastatic melanoma[J].J Clin Oncol,1987,5:1232. 被引量：1
6Ball H G,Blessing J A,Lentz S S,et al.A phaseⅡtrial of paclitaxel in patients with advanced or recurrent adeocarcinoma of the endometrium:a Gynecologiconcology Group study[J].Gynecol Oncol,1996,62(2):278. 被引量：1
7Trimble E L,Adams J D,Vena D,et al.Paclitaxel for platinumrefractory ovarian cancer results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103[J].J Clin Oncol,1993,11:2405. 被引量：1
8Thipen T J,Blessing J A,Ball H,et al.Phase Ⅱ trial of paclitaxel in patients with progressive ovarian carcinoma after platinumbased chemotherapy:a Gynecologiconcology Group study[J].J Clin oncol,1994,12:1728. 被引量：1
3Fennelly D,Aghajanian C,Shapiro F,et al.Phase Ⅰ and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer[J].J Clin Onco1,1997,15(1):187-192. 被引量：1
4Markman M,Hall J,Spitz D,et al.Phase Ⅱ trial of weekly single-agent paclitaxel in platinum /paclitaxel-refractory ovarian cancer[J].J Clin Oncol,2002,20(9):2365-2369. 被引量：1
